Navigation Links
International LDN Awareness Week, October 19 - 25th, 2009
Date:10/1/2009

October 19 - 25th, 2009 has been designated International LDN Awareness Week, to focus media attention on the successful use of the inexpensive generic medication, Low Dose Naltrexone, or LDN. A broad range of diseases respond well to LDN, including Multiple Sclerosis, Crohn's disease, Lupus and Fibromyalgia. Immune system dysfunction appears to be the link. The Fifth Annual Conference on LDN kicks off the week on Oct. 19th, 2009.

Bethesda, MD (PRWEB) October 1, 2009 -- International LDN Awareness Week begins when researchers, physicians and advocates convene on October 19, 2009 at the National Institutes of Health in Bethesda, MD, for the Fifth Annual Conference on Low Dose Naltrexone. There is no charge for the conference; participants register at ProjectLDN.com.

The aim of International LDN Awareness Week is to bring LDN out of the shadows, so more disease sufferers may benefit from the off-label use of this inexpensive generic drug.

Thousands of patients worldwide now enjoy improved health due to LDN. Most learn about it through word of mouth, success stories, Internet research, online forums, and a growing number of doctors who prescribe it for patients with autoimmune diseases. The LDN protocol employs approximately 1/10 the dose of naltrexone, a drug approved in 1984 by the FDA to treat alcoholism and drug addiction.

LDN is changing patients' lives.

"Before I started taking LDN, I was an invalid," says Linda Elsegood, a founder of the LDN Research Trust, a non-profit UK charity, formed in 2004 to raise awareness of and research for LDN. "I had almost every symptom of Multiple Sclerosis: constant fatigue, body numbness, hearing loss, twitching muscles, vertigo. Linda is now almost back to normal. "LDN saved my life. Along with hundreds of others, I'm working to get the word out to patients who desperately need to know about LDN." Linda adds that LDN has virtually no side effects - unlike most of the much costlier, highly toxic medications doctors prescribe to treat MS.

Vicki Finlayson, of Auburn, California, lived a life filled with 9 years of side-effect-laden medications approved by the FDA for MS. "I was on just about every one of these medications, and often on several at once - pain medications, too. My MS got progressively worse, until I was bedridden." In 2005, she found LDN. "I felt improvement in two days." She's now back to normal; all her symptoms are gone. In May, 2008, Vicki did an amazing thing for someone with MS - she walked 53 miles to the State Capitol Building in Sacramento to meet with state officials to raise awareness about LDN. "I'll be back on the Capitol steps October 21st! I'm educating the public, doctors and government officials about this inexpensive, effective treatment. LDN gave me my life back. It's important that I spread the word." Because low dose naltrexone represents an inexpensive, off-label use for a drug approved long ago by the FDA, pharmaceutical companies -- who carry out most of today's drug research -- aren't much interested in funding research on LDN.

Hundreds of patients - and several doctors - who have experienced remarkable results in themselves and their patients, conduct research and raise research funds. One group of US patients raised enough money to help fund a successful trial at the University of California (San Francisco). Trials are being conducted in Mali, Africa and Milan, Italy.

LDN - CLINICAL PRACTICE AND RESEARCH:
Over 20 years ago, naltrexone was approved by the FDA to treat addiction, at much higher doses. But in 1982 Dr. Ian Zagon and other researchers at Penn State discovered its ability, in very low doses, to normalize a dysfunctional immune system. Bernard Bihari, MD, a Harvard-trained New York neurologist, observed positive clinical results using LDN for HIV, MS and other immune system disorders. His observations led to years of treating patients with most immune diseases, including HIV/AIDS, with positive results, and virtually no side effects.

According to Dr. Bihari's friend and colleague, David Gluck, MD, who works tirelessly to educate the public about LDN: "Low Dose Naltrexone may be the most important therapeutic breakthrough in over fifty years. It provides a safe, inexpensive method of medical treatment by mobilizing the natural defenses of one's own immune system."

Dr. Ian Zagon and his colleagues at Penn State are continuing human trials for several disorders, including multiple sclerosis, Parkinson's disease and various cancers; Stanford University is beginning a Phase II trial for fibromyalgia.

Doctors throughout the US, UK, Canada, Italy, Israel, Australia and Nigeria prescribe LDN for their patients.

LDN RESESOURCES, WEBSITES, BOOKS & RADIO SHOW:
Several websites are devoted to LDN, including Dr. Gluck's, lowdosenaltrexone.org; and websites of patient advocates, Linda Elsegood and SammyJo Wilkinson, ldnresearchtrust.org and LDNers.org. These websites help patients and fund research.

Books About LDN:
1. International LDN Awareness Week eBook - 100 Testimonials.
2. Cris Kerr's resource, Those Who Suffer Much KNOW MUCH, features LDN testimonials as case studies.
3. Up the Creek With a Paddle by Mary Boyle Bradley, and LDN interviews, Blog Talk Radio.
4. Free ebook by Julia Schopick, The Faces of Low Dose Naltrexone.
5. The Promise of Low Dose Naltrexone, by Elaine Moore and SammyJo Wilkinson

INTERNATIONAL CONTACTS:

USA Conference, visit ProjectLDN.com.
International LDN Awareness Week, contact:

USA CONTACTS will arrange connections with physicians and patients for interviews about LDN:

SammyJo Wilkinson, SammyJo (at) LDNers (dot) org, (425) 361-2049

Vicki Finlayson, vste (at) att (dot) net, (530) 268-8150

Malcolm West, malcolmwest (at) comcast (dot) net, (484) 580-8564

Organizers of International LDN Awareness Week (October 19-25, 2009):

 
  • Linda Elsegood, LDN Research Trust, UK Internationally supported by:
  • SammyJo Wilkinson, LDNers.org
  • Julia Schopick, HonestMedicine.com
  • Malcolm West, Practical Communications Group

Thanks to Skip's Pharmacy, for supporting the First International LDN Awareness Week. Dr. Lenz will be presenting at the 5th Annual LDN Conference.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb2968694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
International LDN Awareness Week, October 19 - 25th, 2009
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... Atlanta, GA (PRWEB) , ... March 23, 2017 ... ... announced the release of SmartBen NOW, an innovative mobile app and centralized benefits ... gather and present critical information securely from multiple locations. For the first time, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the greater Fort Collins area, has unveiled a collaboration with nonprofit ... involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, ... announced rapid completion of the strategic executive team expansion needed to further optimize ... the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, ... build on a solid foundation. As experts in dangerous situations the Inflow IQ ... coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global capillary electrophoresis market to grow at a CAGR ... Global Capillary Electrophoresis Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/23/2017)... 2017 Newborns are highly vulnerable to ... because their young immune systems typically mount weak ... report achieving strong vaccine responses in newborn animals, ... human trials — by adding compounds known as ... simultaneous papers, they also describe improved adjuvant formulations ...
(Date:3/23/2017)... 23, 2017 Prima BioMed has ... trial of IMP321 in combination with Keytruda, with one ... cohort experiencing a complete response. Recruitment in the second ... to be fully recruited by Q317. Preliminary efficacy data ... cancer study are expected mid-year (recruitment in the 226-patient ...
Breaking Medicine Technology: